We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 10. | 장 마감 후 (AMC) | $-3.27 | — | — | $1.22M | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $1.15 | — | — | $2.74M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-16.43 | — | — | $26.49M |
Consensus PT $43 · 1 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2025. 09. 24. | HC Wainwright & Co. | — | 의견 유지 | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 08. 08. | HC Wainwright & Co. | — | 의견 유지 | Buy → Buy | — | HC Wainwright & Co.: Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-12.19 | — | — | $26.36M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 49,511 | $335.69M | 0.00% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Stored first · Google News · Yahoo Finance (English)
KYNB Stock Price, Quote & Chart | KYNTRA BIO INC (NASDAQ:KYNB) - ChartMill
KYNB Stock Price, Quote & Chart | KYNTRA BIO INC (NASDAQ:KYNB) ChartMill
KYNB Technical Analysis | Trend, Signals & Chart Patterns | KYNTRA BIO INC (NASDAQ:KYNB) - ChartMill
KYNB Technical Analysis | Trend, Signals & Chart Patterns | KYNTRA BIO INC (NASDAQ:KYNB) ChartMill
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Wider-than-Expected Loss Fails to Dampen Investor Sentiment - Profit Margin Analysis - thelegaladvocate.com
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Wider-than-Expected Loss Fails to Dampen Investor Sentiment - Profit Margin Analysis thelegaladvocate.com
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Pre-Revenue Biotech Misses EPS Estimates as Stock Edges Higher - EPS Growth Rate - thelegaladvocate.com
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Pre-Revenue Biotech Misses EPS Estimates as Stock Edges Higher - EPS Growth Rate thelegaladvocate.com
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Pre-Revenue Biotech Misses EPS Estimates as Stock Edges Higher - thelegaladvocate.com
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Pre-Revenue Biotech Misses EPS Estimates as Stock Edges Higher thelegaladvocate.com
KYNTRA BIO (KYNB) CEO Thane Wettig adds 2,800 shares in open-market buy - Stock Titan
KYNTRA BIO (KYNB) CEO Thane Wettig adds 2,800 shares in open-market buy Stock Titan